Angiogensis and CD antigens

We consider everything genesis as a core focus area. This includes embryogenesis, angiogenesis, neurogenesis and stem cell expansion and differentiation. This is important because there is an intersection between reagents and methods for studying embryo development and genesis pathways in "adult systems".

CD antigens serve as markers for growth and development. We are always on the look out for Customer Publications that reference use of these reagents in related applications. Here's one that just pinged our radar.

Karim Harhouri, Abdeldjalil Kebir, Benjamin Guillet, Alexandrine Foucault-Bertaud, Serge Voytenko, Marie-Dominique Piercecchi-Marti, Caroline Berenguer, Edouard Lamy, Frédéric Vely, Pascale Pisano, L'Houcine Ouafik, Florence Sabatier, José Sampol, Nathalie Bardin, Françoise Dignat-George, and Marcel Blot-Chabaud Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood, May 2010; 115: 3843 - 3851
Anti-rat antibodies used in this study are: anti-CD117 (Neuromics) and anti-CD146

Abstract: CD146, an endothelial molecule involved in permeability and monocyte transmigration, has recently been reported to promote vessel growth. As CD146 is also detectable as a soluble form (sCD146), we hypothesized that sCD146 could stimulate angiogenesis. Experiments of Matrigel plugs in vivo showed that sCD146 displayed chemotactic activity on endogenous endothelial cells, and exogenously injected late endothelial progenitor cells (EPCs). Recruited endothelial cells participated in formation of vascular-like structures. In vitro, sCD146 enhanced angiogenic properties of EPCs, with an increased cell migration, proliferation, and capacity to establish capillary-like structures. Effects were additive with those of vascular endothelial growth factor (VEGF), and sCD146 enhanced VEGFR2 expression and VEGF secretion. Consistent with a proangiogenic role, gene expression profiling of sCD146-stimulated EPCs revealed an up-regulation of endothelial nitric oxide synthase, urokinase plasminogen activator, matrix metalloproteinase 2, and VEGFR2. Silencing membrane-bound CD146 inhibited responses. The potential therapeutic interest of sCD146 was tested in a model of hind limb ischemia. Local injections of sCD146 significantly reduced auto-amputation, tissue necrosis, fibrosis, inflammation, and increased blood flow. Together, these findings establish that sCD146 displays chemotactic and angiogenic properties and promotes efficient neovascularization in vivo. Recombinant human sCD146 might thus support novel strategies for therapeutic angiogenesis in ischemic diseases

Image: c-KIT staining of rat skin (epidermis). c-KIT detection was done using anti-rabbit Cy3 conjugated antibodies (red color). DAPI was used to counterstain cell nuclei (blue color).Working dilution: 1:100-1:300.

Related Reagents:

• Immune Response Antibdodies


• Immune Response Proteins


• Cancer Research Antibodies


• Cancer Research Proteins


• Pain and Inflammation Research Antibodies


• Neurodegenerative Disease Antibodies


• Neurodegenerative Disease Proteins


• Apoptosis Research Reagents


• Stem Cell Research Reagents